Summary
The product Nolvadex 20 mg, submitted for independent testing, was analyzed by Janoshik Analytical to verify its composition and potency. The sample, identified by Task Number #37119, was submitted by acepharmaadmin@protonmail.com. The analysis confirmed the presence of Tamoxifen Citrate, with a measured concentration of 19.64 mg, slightly below the labeled claim of 20 mg.
The testing process began on 15 December 2023, with the sample received on 29 December 2023, and analysis completed on 3 January 2024. While the results confirm near-accurate dosing, it remains essential to consider potential batch variances. Independent third-party testing helps validate these findings and ensure consistent product quality across the broader market. This report is shared as an educational resource to support informed decision-making.
Detailed Report
Product Overview
- Product Name: Nolvadex 20 mg
- Manufacturer: Unknown
- Active Ingredient: Tamoxifen Citrate
- Batch Number: Unknown
- Expiration Date: Unknown
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #37119
- Testing Ordered: 15 December 2023
- Sample Received: 29 December 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: ACE Pharmaceuticals (Manufacturer)
- Analysis Paid For By: ACE Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 20 mg (as stated on the label)
- Measured Concentration: 19.64 mg
- Accuracy: 98.2% (0.36 mg below the label claim)
- Variance: -1.8%
Verification Details
- Verification URL: https://janoshik.com/tests/37119_NGHLSM52BYLW
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that the tested Nolvadex 20 mg sample is within an acceptable range of its labeled potency. However, the sample’s submission by an individual rather than an independent source raises questions about product consistency across different batches. While Janoshik Analytical is a reputable laboratory known for its transparency, broader third-party validation would enhance consumer confidence in the product’s overall reliability.
Conclusion
The test results indicate that Nolvadex 20 mg is slightly underdosed, with a measured concentration of 19.64 mg per tablet. While this deviation is minor, it reinforces the need for continuous quality assessment. Consumers should remain cautious and seek independent verification whenever possible. This report aims to promote informed choices and harm reduction strategies.
Disclaimer
This report is for educational and harm reduction purposes. Manufacturer-submitted or individually submitted testing may involve biases, but it provides useful data when critically analyzed alongside independent third-party findings. Readers are encouraged to interpret this information responsibly.
